Tivozanib Hydrochloride Patent Expiration
Tivozanib Hydrochloride is Used for treating advanced renal cell carcinoma by inhibiting angiogenesis with a vascular endothelial growth factor inhibitor in adults with certain treatment histories. It was first introduced by Aveo Pharmaceuticals Inc
Tivozanib Hydrochloride Patents
Given below is the list of patents protecting Tivozanib Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Fotivda | US11504365 | Use of tivozanib to treat subjects with refractory cancer | Nov 05, 2039 | Aveo Pharms |
| Fotivda | US7166722 | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form | Nov 16, 2028 | Aveo Pharms |
| Fotivda | US6821987 | Quinoline derivatives and quinazoline derivatives having azolyl group |
Apr 26, 2025
(Expired) | Aveo Pharms |
Tivozanib Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List